ClinicalTrials.gg
RecruitingNCT07342075DZM-CSVD-RUpdated Jan 15, 2026

Registry Study of Cerebral Small Vessel Disease

An observational study in Cerebral Small Vessel Diseases, Cognitive Impairment and Diffusion Tensor Imaging, sponsored by Dongzhimen Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Dongzhimen Hospital, Beijing · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
50
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Cerebral Small Vessel Diseases with a site in China — 32 open to participants now, 33 under way, 1 of them phase 3. Cerebral Small Vessel Diseases · China.

Planned enrollment
22nd of 22
50 · median 749
Started
2025
with 5 others
Observational
22 of 48
19 open now
Primary completion
2026-08
later than 9 of 32 live
Registered
44th of 48
by date
Lead sponsor
2 of 48
Dongzhimen Hospital, Beijing

Among the 48 studies in Cerebral Small Vessel Diseases with a site in China, this one is the 22nd largest by planned enrollment of the 22 observational ones that give a count, is one of 6 that started in 2025, is one of 22 observational ones, reaches primary completion later than 9 of the 32 other live ones, and was the 44th registered.

Cerebral Small Vessel Diseases

128 studies on the registry are indexed under Cerebral Small Vessel Diseases; 71 are open to participants now.

Browse Cerebral Small Vessel Diseases studies →

Open to participants now

32 of the 48 studies in Cerebral Small Vessel Diseases with a site in China are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 46 Cerebral Small Vessel Diseases studies recruiting now, 26 (57%) set no upper age limit and 5 (11%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Cerebral Small Vessel Diseases with a site in China, or all of them as a file.
02

Study summary

The incidence of cerebral small vessel disease (CSVD) increases with age, affecting approximately 5% of individuals over 50 years old and nearly all individuals over 90 years old. CSVD is also the most important vascular factor contributing to cognitive decline, with 45% of dementia patients attributed to CSVD. Existing interventions are similar to secondary prevention strategies for cardiovascular and cerebrovascular diseases, and no specific therapies are currently available.

CSVD-related cognitive impairment (CSVDCI) predominantly involves attention, processing speed, and executive functions, with relatively preserved memory function, and may be accompanied by non-cognitive clinical manifestations such as gait disturbances, emotional and behavioral disorders, and bladder dysfunction. Although CSVDCI can be classified under vascular cognitive impairment (VCI), there are certain differences in its clinical manifestations.

In summary, it is necessary to develop more targeted treatments for CSVD. We attempt to establish a "symptom-tongue coating-gut microbiota-imaging" system to provide data support for the subsequent exploration of CSVD treatments based on traditional Chinese medicine (TCM) syndrome differentiation and treatment.

03

Conditions studied

  • Cerebral Small Vessel Diseases
  • Cognitive Impairment
  • Diffusion Tensor Imaging
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population mainly consisted of patients from the outpatient and inpatient departments of the Department of Neurology at Dongzhimen Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age above 50 years (including 50-year-old);
  2. MRI confirmed the presence of typical imaging changes of CSVD;
  3. Voluntary participation in the study and be willing to sign the Form.

Exclusion criteria

Exclusion Criteria:

  1. Patients with acute ischemic stroke or acute intracranial hemorrhage (e.g., epidural hematoma, subdural hematoma, subarachnoid hemorrhage, intracerebral hemorrhage, etc.) or a history of cerebral infarction (non-lacunar) or intracranial hemorrhage within the past 3 months;
  2. Significant non-vascular white matter lesions (e.g., multiple sclerosis, adult-onset leukoencephalopathy, metabolic encephalopathy, etc.);
  3. Patients with a history of cognitive impairment due to other causes (e.g., normal pressure hydrocephalus, Alzheimer's disease, Parkinson's disease, multiple sclerosis, encephalitis, etc.);
  4. Severe hepatic, renal, or cardiac insufficiency ( or AST >2 times the , or serum creatinine >1.5 times the upper limit of normal, or [NYHA] functional class III or IV);
  5. Patients with psychiatric disorders that affect study medication administration and evaluation;
  6. to MRI examination (e.g., claustrophobia, presence of an implantable pacemaker, etc.);
  7. Patients unable to comply with follow-up examinations or other study procedures due to residential location or other reasons;
  8. Participation in other clinical trial projects.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patient Gourp
06

What researchers measure

Primary outcomes

  1. Change from baseline in Montreal Cognitive Assessment (MoCA) at 6 month

    Change from baseline in Montreal Cognitive Assessment (MoCA). Score range is 0-30. Higher score means good cognition.

    Time frame: 6 months

Secondary outcomes

  1. Change from baseline in Mini-Mental State Examination (MMSE) at 6 month

    Change from baseline in Mini-Mental State Examination (MMSE). Score range is 0-30. Higher score means good cognition.

    Time frame: 6 months

  2. Changes in whole-brain fiber connectivity at 6 month

    Measure changes in whole-brain fiber connectivity on brain MRI diffusion tensor imaging (DTI).

    Time frame: 6 months

  3. Change from baseline in trail making test (TMT) at 6 month

    Change from baseline in trail making test (TMT).TMT contains TMT-A and TMT-B. Both are related to age and education. The longer the duration of both tests, the poorer the ability to concentrate, process and perform.

    Time frame: 6 months

  4. Change from baseline in Tinetti Performance Oriented Mobility Assessment (POMA) at 6 month

    Change from baseline in Tinetti Performance Oriented Mobility Assessment (POMA). Score range is 0-28. Lower score means higher risk of falling.

    Time frame: 6 months

  5. Change from baseline in instrumental activities of daily living (IADL) at 6 month

    Change from baseline in instrumental activities of daily living (IADL). Score range is 0-24. Higher score means better daily living.

    Time frame: 6 months

  6. Change from baseline in Modified Rankin Scale (mRS) at 6 month

    Change from baseline in Modified Rankin Scale (mRS).Score range is 0-6. Higher score means greater disability.

    Time frame: 6 months

  7. Change from baseline in the symptom at 6 month

    Change from baseline in the symptom. The study plans to analyze whether there are statistically significant differences in the incidence of major symptoms before and after treatment. Patient-reported outcomes (PROs) will be used to record the degree of change in patients' symptoms from baseline (expressed as a percentage, with \>100% indicating symptom worsening and \<100% indicating symptom relief). Meanwhile, baseline and 6-month tongue coating photos will be preserved.

    Time frame: 6 months

  8. Change from baseline in gut microbiota at 6 month

    Change from baseline in gut microbiota. Metagenomic sequencing technology will be applied to the analysis.

    Time frame: 6 months

Other outcomes

  1. Numbers in new vascular events from baseline to 6 month

    New vascular events include ischemic stroke, TIA, cerebral hemorrhage, MI, pulmonary embolism, thrombosis, peripheral arterial occlusion

    Time frame: 6 months

  2. Numbers in all-cause hospitalization from baseline to 6 month

    Numbers in all-cause hospitalization

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Aug 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 15, 2026
StartActual
Nov 13, 2025
Primary completionEst.
Aug 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07342075
Lead sponsor
Dongzhimen Hospital, Beijing
Responsible party
Ying Gao (Prof., Dongzhimen Hospital, Beijing) — Principal investigator
First posted
Jan 15, 2026
Start date
Nov 13, 2025
Primary completion
Aug 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 15, 2026

Study contacts

Beida Ren, PhD
Contact
18810900836@163.com
+86-18810900836

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion